GoAI
Get started
Journey Medical Corporation logo

Journey Medical Corporation

DERM

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$7.75

+$0.26 · +3.47%

Aug 21, 4:00 PM ET

Pre-market

$7.73

−$0.02 · -0.26%

Aug 24, 4:11 AM ET

DERM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

81

Deep Value

Momentum

49

Neutral

Sentiment

49

Mixed

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Claude Maraoui
Listed since
Nov 12, 2021
Employees
58

Market position

Day range

Current $7.75

52-week range

Current $7.75

Open
$7.595
Previous close
$7.49
Volume
264.03K
1.04× average
Average volume
253.27K
Average daily volume
Market cap
213.29M USD
Beta
1.08
Market reference 1
50-day average
$6.6799
+16.02% above average
200-day average
$6.9912
+10.85% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
190.19M USD
P/E (TTM)
-34.31×
P/B (TTM)
6.63×
P/S (TTM)
3.13×
EV / EBITDA
-57.16×
Earnings yield
-6.05%
Free cash flow yield
-6.59%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.24%
Operating margin
-4.41%
Net margin
-8.95%
Return on equity
-35.89%
Return on assets
-12.08%
Return on invested capital
-14.27%

Financial health

Debt / equity
0.8×
Current ratio
1.79×
Altman Z-score
1.44
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends80%26%-29%-83%Gross margin, FY2021: 49.18%Gross margin, FY2022: 58.23%Gross margin, FY2023: 66.33%Gross margin, FY2024: 62.81%Gross margin, FY2025: 59.29%Operating margin, FY2021: -55.25%Operating margin, FY2022: -37.35%Operating margin, FY2023: -2.62%Operating margin, FY2024: -24.36%Operating margin, FY2025: -13.21%Net margin, FY2021: -69.68%Net margin, FY2022: -40.22%Net margin, FY2023: -4.87%Net margin, FY2024: -26.14%Net margin, FY2025: -18.48%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 49.18%. Gross margin FY2022 58.23%. Gross margin FY2023 66.33%. Gross margin FY2024 62.81%. Gross margin FY2025 59.29%. Operating margin FY2021 -55.25%. Operating margin FY2022 -37.35%. Operating margin FY2023 -2.62%. Operating margin FY2024 -24.36%. Operating margin FY2025 -13.21%. Net margin FY2021 -69.68%. Net margin FY2022 -40.22%. Net margin FY2023 -4.87%. Net margin FY2024 -26.14%. Net margin FY2025 -18.48%.

Income trends

Revenue

61.86M USD+10.20%

Operating income

−8.17M USD+40.25%

Net income

−11.43M USD+22.09%
Income trends across reported periods91.5M USD42.23M USD−7.04M USD−56.31M USDRevenue, FY2021: 63.13M USDRevenue, FY2022: 73.67M USDRevenue, FY2023: 79.18M USDRevenue, FY2024: 56.13M USDRevenue, FY2025: 61.86M USDOperating income, FY2021: −34.88M USDOperating income, FY2022: −27.52M USDOperating income, FY2023: −2.07M USDOperating income, FY2024: −13.68M USDOperating income, FY2025: −8.17M USDNet income, FY2021: −43.99M USDNet income, FY2022: −29.63M USDNet income, FY2023: −3.85M USDNet income, FY2024: −14.67M USDNet income, FY2025: −11.43M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 63.13M USD. Revenue FY2022 73.67M USD. Revenue FY2023 79.18M USD. Revenue FY2024 56.13M USD. Revenue FY2025 61.86M USD. Operating income FY2021 −34.88M USD. Operating income FY2022 −27.52M USD. Operating income FY2023 −2.07M USD. Operating income FY2024 −13.68M USD. Operating income FY2025 −8.17M USD. Net income FY2021 −43.99M USD. Net income FY2022 −29.63M USD. Net income FY2023 −3.85M USD. Net income FY2024 −14.67M USD. Net income FY2025 −11.43M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue61.86M USD56.13M USD79.18M USD73.67M USD63.13M USD
Cost of goods sold25.18M USD20.88M USD26.66M USD30.78M USD32.08M USD
Gross profit36.68M USD35.26M USD52.52M USD42.89M USD31.05M USD
Research and development480K USD9.86M USD7.54M USD10.94M USD16.56M USD
Selling, general, and administrative44.37M USD40.2M USD43.91M USD59.47M USD39.83M USD
Operating expenses44.85M USD48.93M USD54.59M USD70.41M USD65.93M USD
Interest income589K USD757K USD322K USD60K USD2K USD
Interest expense3.7M USD2.7M USD1.7M USD2.02M USD7.03M USD
Depreciation and amortization4.35M USD3.52M USD3.86M USD4.37M USD2.56M USD
Operating income−8.17M USD−13.68M USD−2.07M USD−27.52M USD−34.88M USD
Net income−11.43M USD−14.67M USD−3.85M USD−29.63M USD−43.99M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$11.75

51.61% upside
Past 12 months12-month forecastHigh $13.00Average $11.75Low $10.50

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

DERM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding DERM

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.19M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
386.49K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
132.89K
Weight
0.58%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
23.41K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%

Continue in GoAI

Research DERM

research.disclaimer